<table id="t4" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<colgroup>
<col valign="top" width="30%"></col>
<col valign="top" width="20%"></col>
<col valign="top" width="50%"></col>
</colgroup>
<tbody>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Drug Name</content>
</td>
<td>
<content stylecode="bold">Effect on Concentration of Nevirapine or Concomitant Drug</content>
</td>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Clinical Comment</content>
</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Atazanavir/Ritonavir</td>
<td stylecode="Toprule Botrule">↓ Atazanavir<br/>
<br/>
									↑ Nevirapine</td>
<td stylecode="Toprule Botrule" valign="top">Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Clarithromycin</td>
<td stylecode="Toprule Botrule">↓ Clarithromycin<br/>
<br/> ↑ 14-OH clarithromycin</td>
<td stylecode="Toprule Botrule"> Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased.  Because clarithromycin active metabolite has reduced activity against <content stylecode="italics"> Mycobacterium avium-intracellulare complex </content>, overall activity against this pathogen may be altered. Alternatives to clarithromycin, such as azithromycin, should be considered.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Efavirenz</td>
<td stylecode="Toprule Botrule">↓ Efavirenz</td>
<td stylecode="Toprule Botrule">There has been no determination of appropriate doses for the safe and effective use of this combination [<content stylecode="italics">
<content stylecode="emphasis">see Warnings and Precautions <linkhtml href="#s18">(5.4)</linkhtml>
</content>
</content>].</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Ethinyl estradiol and Norethindrone</td>
<td stylecode="Toprule Botrule">↓ Ethinyl estradiol<br/>
<br/>
								↓ Norethindrone</td>
<td stylecode="Toprule Botrule">Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications.  An alternative or additional method of contraception is recommended.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Fluconazole</td>
<td stylecode="Toprule Botrule">↑Nevirapine</td>
<td stylecode="Toprule Botrule">Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Fosamprenavir</td>
<td stylecode="Toprule Botrule">↓Amprenavir<br/>
<br/>
								↑Nevirapine</td>
<td stylecode="Toprule Botrule">Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Fosamprenavir/Ritonavir</td>
<td stylecode="Toprule Botrule">↓Amprenavir<br/>
<br/>
								↑Nevirapine</td>
<td stylecode="Toprule Botrule">No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Indinavir</td>
<td stylecode="Toprule Botrule">↓ Indinavir</td>
<td stylecode="Toprule Botrule">Appropriate doses for this combination are not established, but an increase in the dosage of indinavir may be required.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Ketoconazole</td>
<td stylecode="Toprule Botrule">↓ Ketoconazole</td>
<td stylecode="Toprule Botrule">Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Lopinavir/Ritonavir</td>
<td stylecode="Toprule Botrule">↓Lopinavir</td>
<td stylecode="Toprule Botrule">A dose increase of lopinavir/ritonavir tablets to 500/125 mg twice-daily is recommended when used in combination with nevirapine.<br/>
<br/>A dose increase of lopinavir/ritonavir oral solution to 533/133 mg twice daily with food is recommended in combination with nevirapine.<br/>
<br/>In children 6 months to 12 years of age receiving lopinavir/ritonavir solution, consideration should be given to increasing the dose of lopinavir/ritonavir to 13/3.25 mg/kg for those 7 to &lt;15 kg; 11/2.75 mg/kg for those 15 to 45 kg; up to a maximum dose of 533/133 mg twice daily.<br/>
<br/>Refer to the lopinavir/ritonavir package insert for complete pediatric dosing instructions when lopinavir/ritonavir tablets are used in combination with nevirapine.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Methadone</td>
<td stylecode="Toprule Botrule">↓ Methadone</td>
<td stylecode="Toprule Botrule">Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal.  Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Nelfinavir</td>
<td stylecode="Toprule Botrule">↓Nelfinavir M8 Metabolite<br/>
								↓Nelfinavir C<sub>min</sub>
</td>
<td stylecode="Toprule Botrule">The appropriate dose for nelfinavir in combination with nevirapine, with respect to safety and efficacy, has not been established.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Rifabutin</td>
<td stylecode="Toprule Botrule">↑Rifabutin</td>
<td stylecode="Toprule Botrule">Rifabutin and its metabolite concentrations were moderately increased.  Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity.  Therefore, caution should be used in concomitant administration.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Rifampin  </td>
<td stylecode="Toprule Botrule">↓ Nevirapine</td>
<td stylecode="Toprule Botrule">Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug.  Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine-containing regimen may use rifabutin instead.  </td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Saquinavir/Ritonavir</td>
<td stylecode="Toprule Botrule">The interaction between nevirapine and saquinavir/ritonavir has not been evaluated</td>
<td stylecode="Toprule Botrule" valign="top">The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established. </td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<br/>
<content stylecode="bold italics">Potential Drug Interactions:</content>
</td>
<td stylecode="Toprule Botrule"> </td>
<td stylecode="Toprule Botrule"> </td>
</tr>
<tr>
<td stylecode="Toprule Botrule">
<content stylecode="bold">Drug Class</content>
</td>
<th stylecode="Toprule Botrule">Examples of Drugs
                  </th>
<td stylecode="Toprule Botrule"> </td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Antiarrhythmics</td>
<td stylecode="Toprule Botrule">Amiodarone, disopyramide, lidocaine</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Anticonvulsants</td>
<td stylecode="Toprule Botrule">Carbamazepine, clonazepam, ethosuximide</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Antifungals</td>
<td stylecode="Toprule Botrule">Itraconazole</td>
<td stylecode="Toprule Botrule">Plasma concentrations of some azole antifungals may be decreased. Nevirapine and itraconazole should not be administered concomitantly due to a potential decrease in itraconazole plasma concentrations.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Calcium channel blockers</td>
<td stylecode="Toprule Botrule">Diltiazem, nifedipine, verapamil</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Cancer chemotherapy</td>
<td stylecode="Toprule Botrule">Cyclophosphamide</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Ergot alkaloids</td>
<td stylecode="Toprule Botrule">Ergotamine</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Immunosuppressants</td>
<td stylecode="Toprule Botrule">Cyclosporin, tacrolimus, sirolimus</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Motility agents</td>
<td stylecode="Toprule Botrule">Cisapride</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Opiate agonists</td>
<td stylecode="Toprule Botrule">Fentanyl</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be decreased.</td>
</tr>
<tr>
<td stylecode="Toprule Botrule">Antithrombotics</td>
<td stylecode="Toprule Botrule">Warfarin</td>
<td stylecode="Toprule Botrule">Plasma concentrations may be increased. Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended.</td>
</tr>
</tbody>
</table>